Company
Evommune
Driving the evolution of therapies for chronic inflammatory disease.
Also known as Evommune, Inc
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Evommune, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Evommune was founded to discover and develop innovative therapies that target key drivers of chronic inflammatory disease.
Funding snapshot
- Total raised
- $267MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $115M2024-10-30
Funding rounds
- Round, 2024
- $115M2024-10-30, SEC form D sold, 25 investors
- Round, 2023
- $57.5M2023-03-28, SEC form D sold, 16 investors
- Round, 2021
- $81.8M2021-08-31, SEC form D sold, 10 investors
- Round, 2020
- $12.5M2020-06-22, SEC form D sold, 18 investors
Loading relationship preview